August Troendle Sells 41,331 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 41,331 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $606.88, for a total value of $25,082,957.28. Following the sale, the chief executive officer owned 690,879 shares of the company’s stock, valued at approximately $419,280,647.52. This represents a 5.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Trading Down 0.8%

NASDAQ:MEDP traded down $4.48 during trading hours on Monday, hitting $587.98. 279,025 shares of the company were exchanged, compared to its average volume of 410,590. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $626.26. The company has a fifty day simple moving average of $560.60 and a 200 day simple moving average of $445.45. The stock has a market capitalization of $16.56 billion, a price-to-earnings ratio of 41.12, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.Medpace’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the business posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on MEDP. Robert W. Baird set a $613.00 price objective on Medpace in a research note on Friday, October 24th. BMO Capital Markets began coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Jefferies Financial Group raised their price target on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. TD Cowen upped their price objective on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Finally, Barclays boosted their target price on shares of Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research note on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $487.18.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its holdings in shares of Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after buying an additional 102,015 shares during the period. AQR Capital Management LLC boosted its stake in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the period. Wasatch Advisors LP raised its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Mawer Investment Management Ltd. boosted its position in shares of Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares during the period. Finally, Baillie Gifford & Co. increased its position in shares of Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.